Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, comments how lecanemab slows the progression of Alzheimer’s disease (AD). Prof. Lannfelt attributes this effect to the amyloid cascade hypothesis, which suggests that amyloid beta (Aβ) accumulation triggers a cascade of tau pathology in the brain, and notes that lecanemab’s effects on total tau, phospho-tau, and other downstream biomarkers support this theory. Prof. Lannfelt is optimistic about the potential for early treatment with lecanemab, and speaks about the potential of subcutaneous administration to make it easier for patients. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
